Suddenly, a New Model for Device Acquisitions
This article was originally published in Start Up
The medical device industry has, for a long time, separated naturally into big players and small. But recent consolidation, particularly in areas such as cardiovascular and orthopedic devices, has created an exaggerated dichotomy, with billion-dollar giants on one end, tiny start-ups on the other, and virtually no one in the middle. Now, a small group of investors--among them, Warburg Pincus and Galen Partners-- is trying to find value in what has traditionally been a device company's no man's land, by putting together small and mid-sized companies.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.